Company intelligence / Profile preview

Zhengda

Lianyungang, Jiangsu, Chinasites.google.com ↗

Ownership: Private
Development stage: Other

Overview

Zhengda refers to several active pharmaceutical and biotechnology companies under the umbrella of China Biopharmaceutical/Sino Biopharm. The flagship entity—Zhengda Tianqing Pharmaceutical Group—is one of China's leading pharma groups with strengths across R&D, manufacturing, and commercialization. Its portfolio includes both small molecules and biologics targeting cancer, liver disease, respiratory conditions, surgery/analgesia needs, diabetes mellitus, severe atopic dermatitis, among others. Clinical programs range from preclinical to commercialized drugs.

Therapeutic areas: OncologyEndocrinologyImmunologyDermatologyInfectious Diseases
Modalities: Small moleculeMonoclonal antibody
Industry: Pharma

Partnerships

Collaborations with academic institutions such as Chinese Academy of Agricultural Sciences

Beyond the preview

Go deeper on Zhengda.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhengda.

Explore the full profile